tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Uremia D014511 33 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Stomach Ulcer D013276 75 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Graft Occlusion, Vascular D006083 11 associated lipids
Hypercalcemia D006934 13 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Adenocarcinoma D000230 166 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Bacterial Infections D001424 21 associated lipids
Pain D010146 64 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Genital Diseases, Female D005831 7 associated lipids
Mouth Diseases D009059 5 associated lipids
Meningococcal Infections D008589 3 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Prescott TA et al. A yeast chemical genetics approach identifies the compound 3,4,5-trimethoxybenzyl isothiocyanate as a calcineurin inhibitor. 2014 FEBS Lett. pmid:24374339
Perlman RL and Rao PS Quality of life of older patients undergoing renal transplantation: finding the right immunosuppressive treatment. 2014 Drugs Aging pmid:24399579
Tanaka K et al. Significant association between CYP3A5 polymorphism and blood concentration of tacrolimus in patients with connective tissue diseases. 2014 J. Hum. Genet. pmid:24352002
Kim EJ et al. Costimulation blockade alters germinal center responses and prevents antibody-mediated rejection. 2014 Am. J. Transplant. pmid:24354871
Gołębiewska J et al. Tako-tsubo cardiomyopathy on the first day after renal transplantation - case report and literature review. 2014 Transplant. Proc. pmid:25380951
Ünlüsoy Aksu A et al. Immune thrombocytopenic purpura in a liver transplant patient. 2014 Exp Clin Transplant pmid:24635822
Kamińska D et al. Significant infections after hand transplantation in a Polish population. 2014 Transplant. Proc. pmid:25380943
Bakkour W et al. Successful use of dapsone for the management of circinate balanitis. 2014 Clin. Exp. Dermatol. pmid:24635073
Venkat VL et al. Recurrence of primary sclerosing cholangitis in pediatric liver transplant recipients. 2014 Liver Transpl. pmid:24634351
Kapoor K et al. Lip hypertrophy due to cyclosporine therapy. 2014 Clin. Exp. Nephrol. pmid:23615783
Hartmann A et al. Treatment of generalised vitiligo with tacrolimus 0.1% ointment vs. UVB intense pulsed light phototherapy: a pilot study. 2014 Acta Derm. Venereol. pmid:24473666
Xu H et al. The allo- and viral-specific immunosuppressive effect of belatacept, but not tacrolimus, attenuates with progressive T cell maturation. 2014 Am. J. Transplant. pmid:24472192
Lankarani KB et al. Response to: Comment on: New-onset diabetes and impaired fasting glucose after liver transplant: risk analysis and the impact of tacrolimus dose. 2014 Exp Clin Transplant pmid:24471728
Qi H et al. The antiaging activity and cerebral protection of rapamycin at micro-doses. 2014 CNS Neurosci Ther pmid:25327787
Kabir A Comment on: New-onset diabetes and impaired fasting glucose after a liver transplant: risk analysis and the effect of tacrolimus dosage. 2014 Exp Clin Transplant pmid:24471727
Kuypers DR et al. Combined effects of CYP3A5*1, POR*28, and CYP3A4*22 single nucleotide polymorphisms on early concentration-controlled tacrolimus exposure in de-novo renal recipients. 2014 Pharmacogenet. Genomics pmid:25322286
Kim H et al. Safety of reduced dose of mycophenolate mofetil combined with tacrolimus in living-donor liver transplantation. 2014 Clin Mol Hepatol pmid:25320733
Li CJ et al. Impact of the CYP3A5, CYP3A4, COMT, IL-10 and POR genetic polymorphisms on tacrolimus metabolism in Chinese renal transplant recipients. 2014 PLoS ONE pmid:24465960
Curtin BF et al. Unusually late-onset mycophenolate mofetil-related colitis. 2014 Am J Health Syst Pharm pmid:25320135
Diémé B et al. Assessing the metabolic effects of calcineurin inhibitors in renal transplant recipients by urine metabolic profiling. 2014 Transplantation pmid:24598938
Zheng X et al. Patient with neuromyelitis optica spectrum disorder combined with Sjögren's syndrome relapse free following tacrolimus treatment. 2014 Intern. Med. pmid:25318807
Grillo E et al. Necrobiosis lipoidica. 2014 Aust Fam Physician pmid:24600675
Kimura Y et al. Evaluation of the Multi-ImmunoTox Assay composed of 3 human cytokine reporter cells by examining immunological effects of drugs. 2014 Toxicol In Vitro pmid:24603311
Shilbayeh S The impact of genetic polymorphisms on time required to attain the target tacrolimus levels and subsequent pharmacodynamic outcomes in pediatric kidney transplant patients. 2014 Saudi J Kidney Dis Transpl pmid:24625991
Sagiroglu T et al. Protective effect of everolimus on renal ischemia reperfusion injury in rats. 2014 Saudi J Kidney Dis Transpl pmid:24625994
Wang XZ et al. Increased intracellular adenosine triphosphate level as an index to predict acute rejection in kidney transplant recipients. 2014 Transpl. Immunol. pmid:24211610
Golubović B et al. Total plasma protein effect on tacrolimus elimination in kidney transplant patients--population pharmacokinetic approach. 2014 Eur J Pharm Sci pmid:24184751
Ramachandran R et al. Tacrolimus therapy in adult-onset steroid-resistant nephrotic syndrome due to a focal segmental glomerulosclerosis single-center experience. 2014 Nephrol. Dial. Transplant. pmid:24771498
Daher Abdi Z et al. Exposure to mycophenolic acid better predicts immunosuppressive efficacy than exposure to calcineurin inhibitors in renal transplant patients. 2014 Clin. Pharmacol. Ther. pmid:24968086
Capone F et al. Synergistic antitumor effect of Doxorubicin and tacrolimus (FK506) on hepatocellular carcinoma cell lines. 2014 ScientificWorldJournal pmid:24701168
Danby SG et al. The effect of tacrolimus compared with betamethasone valerate on the skin barrier in volunteers with quiescent atopic dermatitis. 2014 Br. J. Dermatol. pmid:24328907
Kato H et al. Significant improvement of Takayasu arteritis after cord blood transplantation in a patient with myelodysplastic syndrome. 2014 Bone Marrow Transplant. pmid:24317130
Tischer S and Fontana RJ Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting. 2014 J. Hepatol. pmid:24280292
Budde K et al. Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of Phase III, double-blind, randomized trial. 2014 Am. J. Transplant. pmid:25278376
Urbanowicz T et al. Induction therapy, tacrolimus plasma concentration, and duration if intensive care unit stay are risk factors for peripheral leucopenia following heart transplantation. 2014 Ann. Transplant. pmid:25274118
Funaro D et al. A double-blind, randomized prospective study evaluating topical clobetasol propionate 0.05% versus topical tacrolimus 0.1% in patients with vulvar lichen sclerosus. 2014 J. Am. Acad. Dermatol. pmid:24704090
Demmers MW et al. Limited efficacy of immunosuppressive drugs on CD8+ T cell-mediated and natural killer cell-mediated lysis of human renal tubular epithelial cells. 2014 Transplantation pmid:24704664
Størset E et al. Importance of hematocrit for a tacrolimus target concentration strategy. 2014 Eur. J. Clin. Pharmacol. pmid:24071959
Posadas Salas MA and Srinivas TR Update on the clinical utility of once-daily tacrolimus in the management of transplantation. 2014 Drug Des Devel Ther pmid:25210441
Arduino PG et al. Pimecrolimus vs. tacrolimus for the topical treatment of unresponsive oral erosive lichen planus: a 8 week randomized double-blind controlled study. 2014 J Eur Acad Dermatol Venereol pmid:23451852
Wasilewski G et al. Inadequate blood pressure control in orthotopic heart transplant: is there a role of kidney function and immunosuppressive regimen? 2014 Transplant. Proc. pmid:25380929
Taber DJ et al. Significant racial differences in the key factors associated with early graft loss in kidney transplant recipients. 2014 Am. J. Nephrol. pmid:24969370
Keniya MV et al. Drug resistance is conferred on the model yeast Saccharomyces cerevisiae by expression of full-length melanoma-associated human ATP-binding cassette transporter ABCB5. 2014 Mol. Pharm. pmid:25115303
Sun Z et al. Co-administration of Wuzhi capsules and tacrolimus in patients with idiopathic membranous nephropathy: clinical efficacy and pharmacoeconomics. 2014 Int Urol Nephrol pmid:25145781
Dannhorn E et al. De novo use of generic tacrolimus in liver transplantation - a single center experience with one-yr follow-up. 2014 Clin Transplant pmid:25142496
Chatterjea A et al. Suppression of the immune system as a critical step for bone formation from allogeneic osteoprogenitors implanted in rats. 2014 J. Cell. Mol. Med. pmid:24237965
Noceti OM et al. Tacrolimus pharmacodynamics and pharmacogenetics along the calcineurin pathway in human lymphocytes. 2014 Clin. Chem. pmid:25142246
Feliu J et al. Transplant-acquired food allergy (TAFA) following cord blood stem cell transplantation in two adult patients with haematological malignancies. 2014 Br. J. Haematol. pmid:24962133
Ko SF et al. Therapeutic potential of tacrolimus on acute myocardial infarction in minipigs: analysis with serial cardiac magnetic resonance and changes at histological and protein levels. 2014 Biomed Res Int pmid:25114905
Grossman J et al. Nonmyeloablative allogeneic hematopoietic stem cell transplantation for GATA2 deficiency. 2014 Biol. Blood Marrow Transplant. pmid:25111582
Grafals M et al. Immunophenotyping and efficacy of low dose ATG in non-sensitized kidney recipients undergoing early steroid withdrawal: a randomized pilot study. 2014 PLoS ONE pmid:25111080
Freire-Cobo C et al. The calcineurin inhibitor Ascomicin interferes with the early stage of the epileptogenic process induced by Latrunculin A microperfusion in rat hippocampus. 2014 J Neuroimmune Pharmacol pmid:25104570
Bercaw-Pratt JL et al. Clinical recommendation: pediatric lichen sclerosus. 2014 J Pediatr Adolesc Gynecol pmid:24602304
Kaieda S et al. Successful treatment of rectal ulcers in a patient with systemic lupus erythematosus using corticosteroids and tacrolimus. 2014 Mod Rheumatol pmid:24593214
Bica L et al. Neuroprotective copper bis(thiosemicarbazonato) complexes promote neurite elongation. 2014 PLoS ONE pmid:24587210
Little JA et al. The safety and efficacy of noncorticosteroid triple immunosuppressive therapy in the treatment of refractory chronic noninfectious uveitis in childhood. 2014 J. Rheumatol. pmid:24085549
Bergmann TK et al. Population pharmacokinetics of tacrolimus in adult kidney transplant patients: impact of CYP3A5 genotype on starting dose. 2014 Ther Drug Monit pmid:24089074
Aelvoet SA et al. Noninvasive bioluminescence imaging of α-synuclein oligomerization in mouse brain using split firefly luciferase reporters. 2014 J. Neurosci. pmid:25471588
Oh CK et al. Safety and efficacy of conversion from twice-daily tacrolimus to once-daily tacrolimus one month after transplantation: randomized controlled trial in adult renal transplantation. 2014 Yonsei Med. J. pmid:25048494
Matin M et al. The effectiveness of excimer laser on vitiligo treatment in comparison with a combination therapy of Excimer laser and tacrolimus in an Iranian population. 2014 J Cosmet Laser Ther pmid:25046236
de la Fuente V et al. Calcineurin phosphatase as a negative regulator of fear memory in hippocampus: control on nuclear factor-κB signaling in consolidation and reconsolidation. 2014 Hippocampus pmid:25043904
Klintmalm GB et al. Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study. 2014 Am. J. Transplant. pmid:25041339
Ikeuchi H et al. Efficacy and safety of multi-target therapy using a combination of tacrolimus, mycophenolate mofetil and a steroid in patients with active lupus nephritis. 2014 Mod Rheumatol pmid:24252014
Kluk J et al. Follicular mucinosis treated with topical 0.1% tacrolimus ointment. 2014 Clin. Exp. Dermatol. pmid:24252117
Ohe M et al. Successful treatment with tacrolimus of refractory adult-onset Still's disease. 2014 Korean J. Intern. Med. pmid:24648814
Rostaing L et al. The pharmacokinetics of everolimus in de novo kidney transplant patients receiving tacrolimus: an analysis from the randomized ASSET study. 2014 Ann. Transplant. pmid:25017487
Qi H et al. Enhancement of ascomycin production in Streptomyces hygroscopicus var. ascomyceticus by combining resin HP20 addition and metabolic profiling analysis. 2014 J. Ind. Microbiol. Biotechnol. pmid:24965502
Jannot M et al. Early conversion from twice-daily tacrolimus to once-daily extended formulation in renal transplant patients before hospital discharge. 2014 Ann. Transplant. pmid:24999809
Zhao J et al. FK506-loaded chitosan conduit promotes the regeneration of injured sciatic nerves in the rat through the upregulation of brain-derived neurotrophic factor and TrkB. 2014 J. Neurol. Sci. pmid:24954089
Wannhoff A et al. Increased levels of rivaroxaban in patients after liver transplantation treated with cyclosporine A. 2014 Transplantation pmid:25022236
Sureshkumar KK and Chopra B In search of an optimal induction agent in kidney transplantation. 2014 Transplantation pmid:24978038
Welberry Smith MP and Baker RJ The author's reply. 2014 Transplantation pmid:24978039
Hacker C et al. Falsely elevated cyclosporin and tacrolimus concentrations over prolonged periods of time due to reversible adsorption to central venous catheters. 2014 Clin. Chim. Acta pmid:24631133
Goring SM et al. A network meta-analysis of the efficacy of belatacept, cyclosporine and tacrolimus for immunosuppression therapy in adult renal transplant recipients. 2014 Curr Med Res Opin pmid:24628478
Toniutto P et al. Biliary strictures after liver transplantation: role of interleukin 28B genotypes in cyclosporine treated. 2014 Int J Surg pmid:25219480
Hallowell RW and Danoff SK Interstitial lung disease associated with the idiopathic inflammatory myopathies and the antisynthetase syndrome: recent advances. 2014 Curr Opin Rheumatol pmid:25203119
Langone A et al. Long-term dosing patterns of enteric-coated mycophenolate sodium or mycophenolate mofetil with tacrolimus after renal transplantation. 2014 Clin Transplant pmid:24893821
Nafar M et al. Prevalence and risk factors of recurrent cytomegalovirus infection in kidney transplant recipients. 2014 Iran J Kidney Dis pmid:24878947
van Gelder T Within-patient variability in immunosuppressive drug exposure as a predictor for poor outcome after transplantation. 2014 Kidney Int. pmid:24875549
Lalan S et al. Effect of CYP3A5 genotype, steroids, and azoles on tacrolimus in a pediatric renal transplant population. 2014 Pediatr. Nephrol. pmid:24875272
Ricardo E et al. In vivo and in vitro acquisition of resistance to voriconazole by Candida krusei. 2014 Antimicrob. Agents Chemother. pmid:24867987
Tümgör G et al. A case of uneventful ABO-incompatible liver transplantation from a deceased donor managed with routine immunosuppressive treatment. 2014 Turk J Gastroenterol pmid:25599790
Kallash M and Aviles D Efficacy of tacrolimus in the treatment of children with focal segmental glomerulosclerosis. 2014 World J Pediatr pmid:24801235
Maeda H et al. Disappearance of GFP-positive hepatocytes transplanted into the liver of syngeneic wild-type rats pretreated with retrorsine. 2014 PLoS ONE pmid:24796859
Du W et al. Improved FK506 production by the precursors and product-tolerant mutant of Streptomyces tsukubaensis based on genome shuffling and dynamic fed-batch strategies. 2014 J. Ind. Microbiol. Biotechnol. pmid:24788378
Agrawal YP et al. Transplant patient classification and tacrolimus assays: more evidence of the need for assay standardization. 2014 Ther Drug Monit pmid:24784024
Sageshima J et al. Everolimus with low-dose tacrolimus in simultaneous pancreas and kidney transplantation. 2014 Clin Transplant pmid:24779669
Nkongolo S et al. Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor. 2014 J. Hepatol. pmid:24295872
Parashos SA et al. Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience. 2014 JAMA Neurol pmid:24711047
Gillard P et al. Early alteration of kidney function in nonuremic type 1 diabetic islet transplant recipients under tacrolimus-mycophenolate therapy. 2014 Transplantation pmid:24770614
Pandey S et al. Metabotropic glutamate receptor 1 recycles to the cell surface in protein phosphatase 2A-dependent manner in non-neuronal and neuronal cell lines. 2014 J. Neurochem. pmid:25113668
Mitsides N et al. Dapsone-induced methemoglobinemia in renal transplant recipients: more prevalent than previously thought. 2014 Transpl Infect Dis pmid:24215452
Chung BH et al. Decrease of immature B cell and interleukin-10 during early-post-transplant period in renal transplant recipients under tacrolimus based immunosuppression. 2014 Transpl. Immunol. pmid:24709525
Al-Kadhimi Z et al. High incidence of severe acute graft-versus-host disease with tacrolimus and mycophenolate mofetil in a large cohort of related and unrelated allogeneic transplantation patients. 2014 Biol. Blood Marrow Transplant. pmid:24709007
Madian AG et al. Case report: Inability to achieve a therapeutic dose of tacrolimus in a pediatric allogeneic stem cell transplant patient after generic substitution. 2014 BMC Pharmacol Toxicol pmid:25472557
Indriolo A and Ravelli P Clinical management of inflammatory bowel disease in the organ recipient. 2014 World J. Gastroenterol. pmid:24707135
Huang W et al. Tacrolimus (FK506) suppresses TREM-1 expression at an early but not at a late stage in a murine model of fungal keratitis. 2014 PLoS ONE pmid:25464008
Nair S and Waters B Telaprevir in treatment of recurrent hepatitis C infection in liver transplant recipients. 2014 Exp Clin Transplant pmid:24702143
Navas-López VM et al. Successful treatment for ulcerative proctitis with rectal tacrolimus in an 8-year-old girl with intolerance to mesalamine. 2014 Clin J Gastroenterol pmid:26185880
Lee CH et al. Raised tacrolimus level and acute renal injury associated with acute gastroenteritis in a child receiving local rectal tacrolimus. 2014 Clin J Gastroenterol pmid:26183743